<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Genetic and epigenetic factors affecting DNA methylation and gene expression are known to be involved in the development of <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, but the full range of genetic alterations and many key genes involved in the pathogenesis of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> remain to be identified </plain></SENT>
<SENT sid="1" pm="."><plain>NPRL2 is a candidate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene identified in the human chromosome 3p21.3 region </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the role of this gene in the pathogenesis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> by investigating NPRL2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in 55 matched <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> colon tissue samples using quantitative RT-PCR analysis </plain></SENT>
<SENT sid="3" pm="."><plain>There was significantly decreased NPRL2 expression in 45% of the patients </plain></SENT>
<SENT sid="4" pm="."><plain>Lower NPRL2 expression was observed significantly more frequently in poorly differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples than in highly or moderately differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that expression of NPRL2 contributes to progression of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
</text></document>